Please provide your email address to receive an email when new articles are posted on . Incidence rates for second through sixth cSCCs increased (28% to 67%), while time intervals decreased (1.4 to ...
Faricimab increased treatment intervals and decreased CST in previously treated nAMD patients, but BCVA remained unchanged. The study included 88 eyes from 73 patients, with a mean follow-up of 30.1 ...
Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional false negatives Findings reveal substantially ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results